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Abstract 
Rational: Iron deficiency without anaemia is prevalent in patients with idiopathic pulmonary arterial 
hypertension and associated with reduced exercise capacity and survival.  
Objectives: We hypothesised that iron deficiency is involved in the pathogenesis of pulmonary 
hypertension and iron replacement is a possible therapeutic strategy. 
Methods: Rats were fed an iron-deficient diet (IDD, 7mg/kg) and investigated over 4 weeks. 
Measurements and main results: Iron deficiency was evident from depleted iron stores (decreased 
liver, serum iron and ferritin), reduced erythropoiesis and significantly decreased transferrin saturation 
and lung iron stores after 2 weeks IDD. IDD rats exhibited profound pulmonary vascular remodelling 
with prominent muscularization, medial hypertrophy and perivascular inflammatory cell infiltration, 
associated with raised pulmonary artery pressure and right ventricular hypertrophy. IDD rat lungs 
demonstrated increased expression of HIF1α and HIF2α, NFAT and survivin, and STAT3 activation, 
which promote vascular cell proliferation and resistance to apoptosis. Biochemical examination 
showed reduced mitochondrial complex I activity and mitochondrial membrane hyperpolarisation in 
mitochondria from IDD rat pulmonary arteries. Along with upregulation of the glucose transporter, 
GLUT1, and glycolytic genes, hk1 and pdk1, lung 
18
FDG uptake was significantly increased in IDD 
rats. The hemodynamic and pulmonary vascular remodelling were reversed by iron replacement 
(ferric carboxymaltose, 75mg/Kg) and attenuated in the presence of iron deficiency by dichloroacetate 
and imatinib, two putative treatments explored for PAH that target aerobic glycolysis and 
proliferation, respectively.  
Conclusions: These data suggest a major role for iron in pulmonary vascular homeostasis and support 
the clinical evaluation of iron replacement in patients with pulmonary hypertension. 
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Introduction 
There is considerable interest in the role of iron homeostasis in pulmonary hypertension. Iron 
supplementation has been reported to ameliorate, and iron chelation to augment, the rise in pulmonary 
artery pressure seen in healthy volunteers on exposure to altitude
1, 2
. Several independent clinical 
centres have observed that iron deficiency without anaemia is common in patients with idiopathic 
pulmonary arterial hypertension (IPAH), and associated with reduced exercise capacity and survival
3-
6
. These data suggest that iron supplementation may be beneficial in patients with IPAH, and clinical 
studies are in progress to evaluate this hypothesis
7
.  
 
Counter to this argument, studies in rats suggest that iron deficiency may protect against the 
development of pulmonary hypertension
8
. Both contemporaneous treatment with deferoxamine and 
dietary iron restriction attenuate the development of pulmonary hypertension in rats exposed to 
chronic hypoxia or monocrotaline, respectively
9, 10
.  
 
We set out to understand the effect of iron deficiency in the absence of the confounding effects of 
another pulmonary vascular insult. Specifically, we examined the impact of iron deficiency on 
pulmonary haemodynamics, pulmonary vascular structure and cardiac hypertrophy over a 4-week 
time course. After observing striking remodelling of the pulmonary vasculature, we explored whether 
this may be driven by perturbation of mitochondrial biochemistry and a shift in metabolic phenotype. 
We then investigated reversibility of the pulmonary vascular pathology by iron replacement and 
probed the potential mechanisms using targeted therapeutic interventions, the tyrosine kinase 
inhibitor, imatinib
11
 and the metabolic modulator dichloroacetate (DCA)
12
. 
 
Methods 
Animals and experimental design 
Adult male Sprague-Dawley rats (body weight 200-250g; Charles River, UK) were used. All 
experiments were conducted in accordance with the UK Home Office regulations. Experiments were 
designed as follows:  
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a) Iron deficient rat model - time course study: rats were divided into 4 groups (n6) and fed 
with either a standard diet (CTR) or an iron-deficient diet (IDD, 7mg iron/kg; TD.80396, Harlan, UK) 
for 2 (IDD 2WK), 3 (IDD 3WK) and 4 weeks (IDD 4WK). 
b) Iron supplement treatment study: rats were divided into 3 groups (n=6) and fed with (i) a 
standard diet (CTR), (ii) IDD for 4 weeks (IDD 4WK), or (iii) IDD for 4 weeks plus ferric 
carboxymaltose treatment (IDD 4WK+Fe) (Ferinject®, iv. 75mg/Kg; twice a week for two weeks, 
Vifor Pharma) started after two weeks of IDD.  
c) DCA and imatinib treatment study: rats were divided into 3 groups (n=6) and fed with (i) 
IDD for 4 weeks (IDD 4WK), (ii) IDD for 4 weeks with DCA treatment (drinking water, 
70mg/kg/day, sigma) (IDD 4WK+ DCA) and (iii) IDD with imatinib treatment (oral gavage, 
100mg/kg/day, LC laboratory) (IDD 4WK+Imatinib). Treatments were initiated after two weeks of 
IDD and maintained for the remaining two weeks while the rats remained on the IDD.  
d) 
18
FDG PET imaging study: Positron emission tomography with fluorine-18–labeled 2-
fluoro-2-deoxyglucose ligand (
18
FDG-PET) was performed in rats fed with either a standard diet 
(n=5) or an IDD (n=4) for 4 weeks.  
Haemodynamic measurements
 
and tissue collection 
Rats were anaesthetised (Hypnorm 1ml/Kg i.m., Midazolam 0.8 ml/Kg i.p). Right atrial pressure 
(RAP), right ventricle systolic pressure (RVSP) and pulmonary arterial pressure (PAP) were measured 
with a pre-curved catheter inserted through the right jugular vein. Systemic blood pressure (SBP), left 
ventricular systolic pressure (LVSP) and left ventricular end diastolic pressure (LVDP) were assessed 
via carotid artery cannulation. Cardiac output (CO) was measured by thermodilution
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(Supplementary data). Pulmonary vascular resistance (PVR) was calculated using the standard 
equation: (mean PAP – LVDP) / CO. Similarly, systemic vascular resistance (SVR) was calculated as 
(mean SBP – RAP)/ CO. All haemodynamic data were recorded and analysed with a PowerLab Data 
Acquisition system (AD Instruments). 
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At the end of procedure blood was collected to obtain serum. Tissues (lung, heart, liver, skeleton 
muscle) were flushed with saline to clear blood and snap-frozen in liquid nitrogen, and stored at -80 
°C. Hearts were dissected and weighted; the ratio of right ventricle (RV) over left ventricle (LV) plus 
the septum was used as an index of RV hypertrophy (RVH). The left lung was fixed in 10% formalin 
and paraffin-embedded for histological examination 
In vivo 
18
FDG-PET  
In vivo 
18
FDG-PET was performed using a Siemens Inveon small animal multimodality PET/CT 
system (Siemens Healthcare Molecular Imaging). A protocol of 60mins dynamic scanning with 
kinetic analysis established in our lab was employed
14
. The rate of glycolysis was calculated as 
follows: Rate of glycolysis = [Glucose]*Ki ( [Glucose], plasma glucose concentration; Ki , FDG influx 
rate). We assumed the relative glycolytic flux of FDG and glucose (lumped constant) remain 
unchanged between groups
14, 15
. 
Iron markers 
Hemoglobin levels (Hb) were measured by HEMOCUE reader (Sweden) and haematocrit (Hct) using 
a microhaemotocrite device after centrifugation and blood glucose level using a Aviva Accu-Check 
monitor. Circulating iron and unsaturated iron binding capacity (UIBC) were measured in plasma 
(Abbott Diagnostics, Ireland). Transferrin saturation (Tsat) was calculated from the iron and total iron 
binding capacity (TIBC). Ferritin was measured using ELISA (Alpco Diagnostics, USA). For tissue 
iron measurements, 0.1g of tissue was digested in 70% nitric acid, with total iron assessed by means 
of Inductively Coupled Plasma -Mass Spectroscopy (ICP-MS). 
Histology, immunohistochemistry and immunofluorescence 
Lung histology was examined by elastic Van Gieson (EVG) and haematoxylin and eosin (H&E) 
staining. Peripheral vessels <50 µm diameter were counted at x40 magnification and pulmonary 
vascular remodelling was expressed as the proportion of vessels with double elastic lamina (>75% of 
the circumference) to total vessels counted. 
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For immunohistochemistry examination, lung sections were stained for smooth muscle actin (SMA, 
1/200; Sigma), or Von Willebrand factor (VWF, 1/100; Dako), or CD68 (1/200, Serotec), or β-catenin 
(1/100, Abcam), or nuclear factor of activated T-cells 1 (NFAT-1, 1/50, Novus Biological), with 
appropriate horseradish peroxidase conjugated secondary antibodies (1/200). We counted 
macrophages (CD 68
+
) as previously described
16
. 
 
For double immunofluorescence, sections were incubated with GLUT1 (1/50, Abcam), carbonic 
anhydrase (CAIX, 1/100, Novus Biological) and SMA (1/200, Sigma), detected with secondary 
antibodies, Alexa 488 anti-mouse and Alexa 568 anti-rabbit (1/1000; Invitrogen), with mounting 
solution containing DAPI. Images were obtained with a Leica laser confocal microscope (TCS SP2 
AOBS). 
 
Western blotting 
Protein samples (25 µg), extracted from lung homogenates, were run on a precast gel (Invitrogen) and 
transferred to a nitrocellulose membrane. Western blotting was performed as per manufacture’s 
suggestions (rabbit anti-survivin antibody 1/1000, ProteinTech; rabbit anti HIF2α 1/1000, mouse anti 
HIF1α 1/1000, mouse anti NFAT-1, 1/1000, Novus Biological; mouse anti Bcl-2 1/1000, BD 
Bioscience; anti STAT3 1/2000, anti phospho-STAT3 1/2000, Abcam). Proteins were detected by 
Novex enhanced chemiluminescent (ECL) kit (Invitrogen, Paisley, UK). Optical densities of 
individual bands were measured and protein expression were standardised with β actin. 
Real Time-PCR analysis 
Total RNA was extracted by RNeasy Mini Kit (Quiagen) and reversed transcribed with M-MLV 
Reverse Transcriptase (Promega). Real Time PCR for GLUT1, pyruvate dehydrogenase kinase 1 
(pdk1) and hexokinase 1 (hk1) was performed using pre-designed, gene-specific TaqMan primer and 
probe sets (Applied Biosystems). Gene expression data were normalized with the housekeeping ubc1 
expression and analysis was carried out using the relative expression software tool (REST). 
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Mitochondrial isolation and measurement of complex I activity 
Mitochondria were isolated from control or IDD rat pulmonary arteries (PA, 2
nd
 to 6
th
 division). 
Briefly, freshly dissected tissues were homogenized in ice-cold isolation buffer (250 mM sucrose, 20 
mM HEPES, pH 7.2, 1 mM EDTA, and 0.5% BSA) and centrifuged at 2500x g to pellet nuclear 
material. The supernatant was centrifuged at high-speed (9600 x g for 15 min at 4°C); the pellet was 
washed twice in isolation buffer by centrifugation at 9600x g.  Mitochondria were frozen and stored at 
-80°C until use. Mitochondrial complex I activity was measured using an immunocapture enzyme 
activity assay according to manufacturer’s instructions (Abcam).  
 
Mitochondrial inner membranes were also isolated from mitochondria from control and IDD rat 
pulmonary arteries (n=3) and purified by centrifugation. Patch clamp recordings were performed to 
measure the mitochondrial inner membrane peak conductance levels (Supplemental material). 
Cell culture 
Human pulmonary artery smooth muscle cells (PASMCs) were serum-deprived and then stimulated 
with 50ng/ml platelet-derived growth factor (PDGF) with or without iron chelator deferoxamine 
(DFO, 200µM, Sigma) for 48 hours. Final cell count or WST-1 based colorimetric assay was 
performed (Roche).  
 
A separate set of PASMCs were cultured with or without 200µM DFO for 24 hours and then 
incubated with fluorescence probes for 30 minutes at 37C in the dark. Mitochondrial membrane 
potential was determined using 20nM tetramethylrhodamine (TMRE; Life technologies). Reactive 
oxygen species (ROS) production was detected using 5µM CellROX Green (Life technologies). 
Hoechst (Life technologies) was used for nucleus staining. Images were obtained with a Zeiss Axio 
microscope. 
Statistics 
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Data are presented as mean ± SEM. Normal distribution was verified employing the Kolmogorov-
Smirnov test and variance of homogeneity was tested by the Levene test. Differences between groups 
were assessed by either Student t-test or appropriate ANOVA followed by Bonferroni post hoc test for 
multiple group comparisons. A value of p<0.05 was considered statistically significant. All statistical 
analyses were performed with Prism 5 (GraphPad Software, Inc.). 
 
Results 
Establishment of iron deficient rat model 
Rats were maintained on an IDD for up to 4 weeks and iron status evaluated (Table 1; Online Figure 
Ia). Both stored and circulating iron levels were reduced following 2 weeks IDD, as reflected in the 
significantly decreased liver (<30% of control) and serum (<20% of control) iron levels, blood ferritin 
and Tsat, while UIBC increased (p<0.05). This was accompanied by reduced Hb (109g/L versus 147 
g/L) and Hct (38% versus 48%) in IDD rats, maintained through to 4-weeks. Lung and skeletal 
muscle tissue iron levels were significantly reduced over the 4 weeks (69% and 63% of control, 
respectively), while RV and LV tissue iron levels were reduced to 78% and 90% of control level. 
Iron deficient rat develops pulmonary hypertension  
IDD rats developed progressive pulmonary hypertension over the 4-week time course. Mean PAP and 
RVSP were elevated significantly by 3 weeks in IDD rats compared with controls, but SBP was not 
affected ((Figure 1a & b; Online Figure Ib). RVH was evident at 4 weeks in IDD rats (Figure 1c). LV 
and total heart weight (corrected for body weight) were also increased in the 2-week iron deficient rat 
(Online Figure 1c & d), as previously reported
17
. There was a trend of increasing in LV systolic 
pressure (Online Figure Ie). Cardiac output was significantly increased at 4 weeks compared to the 
control group (135%, P<0.05) (Figure 1d, Online Figure If). PVR was significantly increased in 4-
week IDD rats, but not SVR (Figure 1e & f). 
 
Histological examination of lung sections revealed profound pulmonary vascular remodelling in iron 
deficient rats (Figure 2, Online Figure IIa). SMA staining demonstrated tunica media hypertrophy in 
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vessels with diameter <50 µm or 50 to 100µm (Figure 2a & b, Online Figure IIa), with an increased 
proportion of peripheral vessels (<50m) demonstrating muscularization (Figure 2c). These structural 
changes were accompanied by a reduction in lumen area, protruding endothelial cells and 
concertinered appearance to the inner elastic lamina (Figure 2a & b). Prominent infiltration of 
macrophages (CD68
+
) with a preferential accumulation surrounding the peripheral remodelled vessels 
was also evident in iron deficient rats (Figure 2d & e, Online Figure IIb).  
 
Increased HIF1α and HIF2α expressions, and STAT3 activation in the iron deficient rat lung   
To better understand the molecular drivers of pulmonary vascular remodelling, we first investigated 
HIF1α and HIF2α levels. Iron is required for the optimal activity of prolyl hydroxylases (PHDs), 
which act to degrade hypoxia inducible factors
18, 19
. Western blots show an increase in both HIF1α 
and HIF2α levels in the iron deficient rat lung (Figure 3a). Consistent with HIF1α stabilisation under 
iron deficient conditions, expression of CAIX, a downstream response of increased HIF1α, was 
increased in the remodelled vasculature (Figure 3b, Online Figure IIIa).  
 
Following up on the finding of inflammatory cells in IDD lungs, and reports that iron deficiency can 
cause a proinflammatory state
20
, we also measured levels of signal transducers and activators of 
transcription-3 (STAT3). This cytoplasmic latent transcription factor is activated by phosphorylation 
in response to cytokines and recently proposed to act a signalling hub in PAH
21
. Levels of 
phosphorylated STAT3 were increased in IDD rat lungs (Figure 3 c-e), indicating STAT3 
activation. The nuclear factor of activated T cells, NFAT, increases the transcription of multiple 
inflammatory mediators such as interleukins and tumor necrosis factor, and contributes directly to 
recruitment of inflammatory cells in remodeled vessels
22
. Increased NFAT expression was evident in 
the IDD rat lung with increased expression in remodelled vessels (Figure 3 f, g).  
 
Both STAT3 and NFAT activation have been associated with altered/suppressed mitochondrial 
function
22-24
, potentiating a hyperproliferative and antiapoptotic cell phenotype, and in keeping with 
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this, we observed a 3-fold increase in the antiapoptotic regulator Bcl2 in the IDD rat lung (Online 
Figure IIIb). 
 
Iron deficiency induces alteration of mitochondrial function in vitro and in vivo 
To investigate further mitochondrial activity in the presence of reduced iron, we first measured the 
direct effects of iron deficiency on mitochondrial function in human PASMCs in culture. A global 
index of mitochondrial function is the mitochondrial membrane potential. We observed 
hyperpolarization of the mitochondrial membrane potential (ΔΨm) as measured by the positively 
charged dye TMRE (Figure 4a) and inhibition of reactive oxygen species (mROS) generation (Figure 
4b). Accompanying this, iron chelation increased metabolic activity and cell proliferation (Figure 4c, 
d). 
 
Iron is a critical substrate for mitochondria and iron-sulfur clusters (Fe-S) exclusively formed in 
mitochondria are essential components of electron transport chain complexes and enzymes like 
succinate dehydrogenase and aconitase
24
, impacting on mitochondrial function directly. We measured 
mitochondrial complex I activity, the first enzyme in the mitochondrial respiratory chain, by 
immunocapture of NAD+ in mitochondria extracted from pulmonary arteries. In IDD rats (n=4), 
complex I activity was reduced compared to control animals (Figure 4 e & f). Patch clamp 
measurements on mitochondrial inner membrane vesicles using a recently modified technique
25, 26
 
showed a drop in ion channel peak conductance levels in IDD rats (51.210.5, n=5) compared to 
controls (109.210.5, n=5), consistent with altered mitochondrial function (Online Figure IVa, b). 
 
Increased glucose uptake in the iron deficient rat lung 
We reasoned that perturbation of mitochondrial function would result in a glycolytic phenotype, 
detectable using 
18
FDG PET. Dynamic PET acquisition with kinetic analysis
14
 demonstrated a 
significant increase in lung 
18
FDG uptake in 4 week IDD animals compared to controls (Figure 5a, b 
& c). The calculated glycolysis rate ([glucose]× Ki) was also significantly elevated in IDD rat lungs 
(Figure 5d). Blood glucose levels in non-fasting 4 week IDD rats were significantly increased 
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compared to controls (IDD 4WK 10.5 ± 2.1; CTR 8.3 ± 0.11; mmol/L, p<0.05) (Figure 5e), as 
previously observed
20, 21
. 
 
Consistent with increased 
18
FDG uptake, the remodelled pulmonary vessels demonstrated prominent 
GLUT1 expression by immunofluorescence (Figure 5f). Real time PCR analysis of IDD rat lungs 
showed increased expression of glut1 (>2 fold) along with hk1 and pdk1 (3 and 2 fold respectively) 
(Figure 5g).  
Iron supplementation treatment attenuates pulmonary hypertension in iron deficient rat 
To demonstrate reversibility of the pulmonary vascular phenotype, we administered intravenous iron 
(Ferinject) to 2 week IDD rats
7
. Iron supplementation for 2 weeks elevated circulating iron indices 
and tissue iron levels and restored erythropoiesis in IDD rats to control levels (Table 1).  
 
Iron treatment reduced PAP  (22 ± 1.6 vs 27 ± 0.6, mmHg, p<0.05), normalised RV mass (Figure 6a, 
b), and reduced pulmonary vascular muscularization (Figure 6c, Figure 2a & b) and perivascular 
macrophage accumulation (Figure 6e, f & g; Online Figure IIa) compared to 4 week IDD rats. Blood 
glucose concentration was also reduced to control levels (7.8 mmol/L ± 0.7) (Figure 6f). 
DCA and imatinib attenuate pulmonary hypertension in iron deficient rat 
To examine the role of metabolic dysfunction in the development of pulmonary hypertension in IDD 
rats, rats with established iron deficiency were treated with DCA, an inhibitor of pyruvate 
dehydrogenase kinase (PDK)
11, 12
 for 2 weeks while remaining on the IDD. Inhibition of PDK 
facilitates mitochondrial oxidative phosphorylation and has been reported to attenuate pulmonary 
hypertension in a number of experimental models. DCA attenuated the rise in PAP (Figure 7a) and the 
associated RV hypertrophy (Figure 7b) and pulmonary vascular remodelling (Figure 7c; Online 
Figure IIa, b) seen in iron deficiency. Cardiac output was also decreased to control levels (Figure 7d).  
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An alternative strategy for probing the metabolic phenotype in our model is to treat with imatinib, a 
tyrosine kinase inhibitor that downregulates GLUT1. Two weeks treatment with imatinib also reduced 
PAP and remodelling in the presence of persistent iron deficiency (Figure 7a-d). 
 
Increased oncogenic protein survivin expression in iron deficient rat lung 
Survivin, an inhibitor of apoptosis, is expressed in established human and experimental PAH and has 
been etiologically associated with the development of PAH
27
. Survivin expression was increased in 
the IDD rat lung and tracked pulmonary remodelling severity. Both DCA and imatinib reduced 
survivin expression in the lung, consistent in other animal models
28, 29
 (Figure 7e & f). Survivin has 
been identified as a target gene for Wnt/β-catenin signalling30. β-catenin was observed to be expressed 
mainly in the vascular cell membrane in control rat lungs, but translocated to the nucleus of vascular 
cells (e.g. endothelial cell and SMC), indicating Wnt pathway activation in IDD rat lungs (Figure 7g). 
 
Discussion 
 
We report for the first time profound vascular remodelling of pulmonary arterioles as a consequence 
of chronic iron deficiency in rats. The pulmonary vascular changes were associated with raised PAP, 
PVR and RV hypertrophy and accompanied by activation of HIF, STAT3, and mitochondrial 
dysfunction associated with a glycolytic phenotype. Both the hemodynamic and pulmonary vascular 
changes were reversed by iron replacement. Significantly, pulmonary remodelling was attenuated in 
the presence of persistent iron deficiency by DCA and imatinib
11, 12
, two putative investigational 
treatments for PAH that target aerobic glycolysis and cell proliferation, respectively. 
 
Iron deficiency was achieved by restricting dietary iron to 7 mg/kg per day, a regimen employed by 
other investigators
31-33
. By two weeks, liver iron stores and serum iron and ferritin were substantially 
reduced (<30% of control level) and remained low. Hb and Hct were also reduced but to a lesser 
degree (25%). Hb remained >100g/L for the duration of the experiment, above the 70-90g/L range 
regarded as moderate anaemia in the rat
2
. Lung tissue iron levels were significantly reduced in IDD 
rats (69% of control), while RV iron levels were reduced to 78% of control level. 
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The pulmonary vascular remodelling observed in the IDD rats is striking and appears more severe 
than described in most reports of monocrotaline and hypoxia-induced pulmonary hypertension. There 
are notable similarities with human PAH
34-38
, specifically medial hypertrophy coupled with an 
abnormal intimal endothelium and perivascular inflammatory cell infiltration. In contrast to the 
pulmonary hypertension phenotype, systemic pressure and systemic vascular resistance were not 
affected in IDD rats. That said, cardiac output was elevated in 2 week and 4 week IDD rats (112% and 
135% of control respectively), most likely in response to the reduced Hct and Hb from iron 
deficiency, and increased shear stress from increased pulmonary blood flow may contribute to the 
pulmonary vascular changes observed. 
 
Support for a direct effect of iron deficiency on pulmonary vascular remodelling comes from the 
effect of iron chelation on PASMC proliferation in culture. In vivo, vascular remodelling was 
accompanied by increased expression of HIF1α and HIF2α protein, and downstream targets, CAIX 
and GLUT1, biochemical signatures of iron deficiency-induced “tissue hypoxia”39 and integral to the 
pulmonary vascular remodelling observed in human IPAH and several experimental models of 
pulmonary hypertension
40-42
.  
 
Inflammation is also recognised as a mediator of pulmonary vascular remodelling in many 
presentations of pulmonary hypertension and may participate in that associated with iron deficiency. 
The relationship between inflammation and iron deficiency is complex but there is evidence that the 
low hepcidin levels associated with iron deficiency can cause a proinflammatory state
43
. The presence 
of macrophages in the IDD rat lung is relevant here, as is the activation of STAT3 and NFAT
22, 23
; 
both integrate signalling from cytokines but also growth and angiogenic factors and effect actions 
through a number of downstream targets, including Bcl2 and survivin. 
 
Collectively, the activated HIF, STAT3 and NFAT signalling would be expected to support a 
proproliferative and anti-apoptotic state. An important manifestation of this cellular phenotype is 
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mitochondrial dysfunction, associated with a metabolic shift to glycolysis, referred to as the “Warburg 
effect” in oncology and postulated to play a central role in the pathogenesis of PAH12, 14, 24. We found 
that iron chelation induces hyperpolarization of the mitochondrial membrane potential and the 
inhibition of ROS generation in PASMCs in culture. There is also clear evidence for mitochondrial 
dysfunction in vivo. Mitochondria from IDD rat PAs demonstrated decreased mitochondrial complex I 
activity along with reduced baseline inner membrane conductance levels in comparison to control 
specimens. Consistent with increased expression of glut1 and the glycolysis enzymes, hk1 and pdk1, 
in IDD rat lungs, parenchymal 
18
FDG uptake was increased, along with glycolysis as measured by 
dynamic PET scanning.  
 
The pulmonary hypertension phenotype induced by iron deficiency is reversible with iron 
supplementation. We chose intravenous ferric carboxymaltose as it has previously been used in heart 
failure
44, 45
 and is currently under study in a clinical trial in PAH
7
. Of greater interest, the elevated 
PAP and vascular remodelling were attenuated by treatment with the metabolic modulator, DCA
12
, 
and the anti-proliferative tyrosine kinase inhibitor, imatinib
11
, in the presence of persistent iron 
deficiency. DCA acts by inhibition of PDK to restore oxidative phosphorylation
46
 and so reverses the 
metabolic shift induced by iron deficiency. Imatinib, through inhibition of PDGF, influences glucose 
metabolism by translocalization of GLUT1 transporters from the cell membrane into the cytosol and 
by inhibiting glycolysis and promoting mitochondrial oxidative glucose utilization
47
. 
 
Our observations that iron deficiency leads to pulmonary hypertension is congruent with studies in 
humans that suggest iron deficiency augments the pressure response to hypoxia at altitude
3, 4
 and is 
associated with a poor prognosis in PAH
3-6
. It is at odds with two studies in rats, both of which 
suggest iron deficiency is protective against hypoxia-induced and monocrotaline-induced pulmonary 
hypertension
9, 10
. However, both these studies have confounding factors. Polycythemia is an important 
contributor to hypoxia-induced pulmonary hypertension; the lower haemoglobin associated with iron 
deficiency in that model would be expected to be beneficial, as indeed it is in Tibetans acclimatised to 
high altitude
48, 49
. In the case of monocrotaline, inflammation plays a major role in the genesis of the 
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vascular lesion and iron deficiency can alter the inflammatory response. Examination of the effects of 
iron deficiency in the absence of hypoxia or monocrotaline provide a more potent approach to unmask 
the effects of tissue iron depletion alone. 
 
An important observation is that the lung, like the liver, is susceptible to iron depletion during dietary 
iron deficiency, more so than the myocardium. Iron deficiency is important in heart failure and has 
received considerable attention in recent years
50
. Iron supplementation has been shown to improve 
well-being and exercise capacity in patients with left heart failure
44, 45
. It remains to be seen whether it 
improves survival. In this study we did not study cardiac function in detail. Both the LV and RV 
showed evidence of hypertrophy in the iron deficient rat. But in keeping with pulmonary 
hypertension, the RVH index (RV/LV+sep) was increased and responded to iron replacement, as well 
as treatment with DCA and imatinib.  
 
In summary, we have shown that chronic iron deficiency in the absence of other disease activates 
HIF, STAT3, glycolysis, NFAT and survivin and leads to a shift in pulmonary vascular cellular 
bioenergenetics towards aerobic glycolysis. The accompanying mitochondrial dysfunction, apoptosis 
resistance and inflammatory cell infiltration contribute to the striking pulmonary vascular remodelling 
in the iron deficient rat (Figure 8). As iron deficiency can exert pathological effects on the pulmonary 
vasculature, our observations lend support to further clinical evaluation of iron supplementation for 
iron deficient patients with PAH. 
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Legends  
Figure 1. Time course of development of pulmonary hypertension phenotype. a) Mean pulmonary 
arterial pressure (PAP); b) Systemic pressure; c) Right ventricular (RV) hypertrophy (RV/ LV+sep; d) 
Cardiac output; e) Pulmonary vascular resistance (PVR); f) Systemic vascular resistance (SVR). Rats 
were fed with an iron deficient diet for 2 weeks (IDD 2WK), 3 weeks ( IDD 3WK) and 4 weeks (IDD 
4WK) (n≥6). Group comparisons were made with one-way ANOVA and Bonferroni post hoc test. 
***P<0.001, **P<0.01 and *P<0.05 vs control (CTR); #p<0.05 between other groups. 
Figure 2. Histological examination of lung peripheral vasculature showing vascular remodeling in 
iron deficient rats at 2 weeks (IDD 2WK), 3 weeks (IDD 3WK], and 4 weeks (IDD 4WK), and IDD 
rats treated with ferric carboxymaltose (IDD 4WK+Fe) compared with controls (CTR). Smooth 
muscle actin (SMA), Von Willebrand factor (VWF), elastic Van Gieson (EVG), haematoxylin and 
eosin (HE) of a) vessels < 50m and b) vessels 50 to 100m. Bar=50m. c) Percentage of 
muscularized vessels (n≥4); d) Total macrophages (CD68) per mm2 in lungs of IDD 4WK rats 
compared to CTR (n=6); e) Number of macrophages (CD68

) per mm
2
 in close proximity to vessels 
<50m in lungs of controls and IDD rats (n=6). Section were counterstained with Gill’s 
haematoxylin; (400x, Bar=50m). Groups’ comparison was made with one-way ANOVA and 
Bonferroni post hoc test. *p<0.05 vs control (CTR); #p<0.05 between other groups. 
Figure 3. a) Representative western blot bands and summary data of lung HIF1 and HIF2 protein 
expression (normalized to β-actin) in control, 2 weeks iron deficient (IDD 2WK) and 4 weeks iron 
deficient (IDD 4WK) rats (n=5 each group). b) Representative pictures of carbonic anhydrase IX (CA 
IX, green) and smooth muscle actin (SMA, red) double immunofluorescence of lung sections of IDD 
4WK and CTR animals showing CA IX expression in the remodelled vessels. Bar=50m. c-f) 
Representative western blot bands and summary data of lung STAT3 and phospho-STAT3 protein 
expression (normalized to β-actin) in control and IDD 4WK rats (n=5 each group). g) Lung nuclear 
factor of activated T-cell (NFAT) protein expression in CTR (n=5), IDD 2WK and IDD 4WK rats 
(n=5). h) NFAT localization in the remodeled vessels of IDD 4WK compared to CTR, Bar=50m. All 
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western quantification were normalised to β-actin and presented as mean±SEM of fold change 
compared to control. *p<0.05 vs control group by one-way ANOVA and Bonferroni post hoc test on 
selected columns. 
Figure 4. Effects of iron chelator deferoxamine and ferric carboxymaltose on human pulmonary 
smooth muscles cells (hPSMCs) in culture. a-d)Representative confocal images and mean data of a) 
mitochondrial membrane potential  measured by the positively charged dye TMRE and b) ROS 
production (nuclei are stained blue by Hoechst) in live hPSMCs; c) cell count and d) metabolic 
activity in hPSMCs following deferoxamine (DFO, 200μm) and iron treatment (Fe, 200µm) compared 
with untreated controls (CTR). e) Representative mitochondrial complex I activity, from 
immunocaptured of NAD+ and recorded over 30mins. f) Summary complex I activity results 
expressed as mean OD/min and presented as fold change compared to control (n=4 each group,  
***p<0.0001 vs control).  
Figure 5. a) Lung 18FDG influx rate (Ki) from Patlak analysis in control (CTR) and 4 week iron 
deficient rats (IDD 4WK) (n=6). b) Representative static images from dynamically acquired PET 
images 60 minutes after 
18
FDG injection. c) Measurement of lung 
18
FDG uptake by gamma counter in 
CTR and IDD 4WK; %ID/gm, percentage of injected dose per gram of tissue. d) Rate of glycolysis 
calculated from influx rate. e) Blood glucose concentration (non-fasted) in CTR and IDD 4WK (n≥3). 
f) Representative lung sections with double immunofluorescence of glucose transporter 1 (GLUT-1) 
in the remodelled vessels of IDD 4WK rat; smooth muscle actin (SMA, green), GLUT-1, red; 
Bar=100m. g) Levels of expression of glucose transporter 1 (glut1), pyruvate dehydrogenase kinase 
1 (pdk1) and hexokinase 1 (hk1) in IDD 4WK rat lungs; data are presented as fold changed compared 
to controls (baseline) (n=3); fold changes were calculated using the REST software. Each group were 
compared to control using Student’s t-test, *p<0.05.  
Figure 6. Ferric carboxymaltose ameliorates PAH phenotype. a) Mean PAP; b) RV Hypertrophy; c) 
Percentage of muscularized vessels (n≥5); d) Total macrophages (CD68) per mm2 in lung (n=6); e) 
Number of macrophages (CD68

) per mm
2
 in close proximity to vessels in lung (<50m) (n=6); f) 
blood glucose levels. Data from 4 weeks iron deficient rat (IDD 4WK) and IDD rat treated with ferric 
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carboxymaltose (IDD 4WK+Fe) are compared with controls (CTR). Group comparisons were made 
with one-way ANOVA and Bonferroni post hoc test. *p<0.05 vs control (CTR); #p<0.05 vs IDD 
4WK+Fe. 
Figure 7. Effects of DCA and imatinib treatments on hemodynamics, pulmonary vasculature and 
survivin expression. a) Mean PAP; (b) RV hypertrophy; c) Percentage of muscularized vessels (n≥4); 
d) Cardiac output (n≥6); (e) Representative pictures of EVG and SMA staining on lung sections; and 
f) Representative bands and summary data of lung survivin protein expression levels in control (n=5), 
2 weeks iron deficient (IDD 2WK), 4 weeks iron deficient (IDD 4WK), 4 weeks iron deficient + 
dichloroacetate (DCA), and 4 weeks iron deficient + imatinib (n=4). Western blot data are normalized 
to β-actin. and presented as mean±SEM of fold change compared to control. Groups were compared 
by one-way ANOVA and Bonferroni post hoc test on selected columns, *p<0.05 vs control, #p<0.05 
between other groups. g) Representative pictures show -catenin localization in the nuclei of smooth 
muscle cells (arrow) and endothelial cells (open arrow) in iron deficient lung, Bar=50m. 
Figure 8. Cellular changes in the iron deficient state. Chronic iron deficiency activates hypoxia 
induced factor (HIF1), signal transducers and activators of transcription-3(STAT3), lung nuclear 
factor of activated T-cell (NFAT) and survivin; and leads to a shift of pulmonary vascular cellular 
bioenergenetics towards aerobic glycolysis, a proinflammatory state and mitochondrial dysfunction. 
The consequent pulmonary vascular cell apoptosis resistance, hyper-proliferation and inflammatory 
cell infiltration contribute to the striking pulmonary vascular remodelling in the iron deficient rat. 
Treatments targeted at restoring normal mitochondrial activity with an inhibitor of pyruvate 
dehydrogenase kinase (PDK) known to promote mitochondrial oxidative phosphorylation, 
dichloroacetate (DCA), and an antiproliferative tyrosine kinase inhibitor which acts to downregulate 
glucose transporter (GLUT1), imatinib, attenuate pulmonary hypertension and vascular remodeling in 
the presence of persistent chronic iron deficiency.  
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Table 1. Iron markers and tissue iron levels. Iron deficient rats were fed with an iron restricted diet 
(7mg iron/kg) for 2 weeks (IDD 2WK), 3 weeks (IDD 3WK) and 4 weeks (IDD 4WK) (n≥3). Iron 
replete rats were fed with an iron deficient diet for 4 weeks, with ferric carboxymaltose treatment 
introduced for the last 2 weeks (75 mg/Kg, twice a week) (IDD 4WK+Fe) (n≥3). Group comparisons 
were made with one-way ANOVA and Bonferroni post hoc test. *p<0.05 vs control (CTR); # p<0.05 
vs 4 weeks iron deficient (IDD 4WK). 
 
 
  
* p<0.05 compared to control 
# p<0.05 compared to IDD 4WK 
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Figure 1. 
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Figure 2. 
 
 
 
c	 d	
*	
e	
*	
a	
IDD	3WK	
SM
A
	
EV
G
	
H
E	
IDD	4WK	IDD	2WK	CTR	
V
W
F	
4WK	IDD+Fe	 IDD	3WK	
SM
A
	
EV
G
	
H
E	
IDD	4WK	IDD	2WK	CTR	
V
W
F	
b	
IDD	4WK+Fe	
#	
*	 *	
Muscularised vessels (<50µm) 
29 
 
Figure 3. 
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Figure 4. 
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Figure 5. 
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Figure 7. 
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Figure 8. 
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Novelty and Significance 
What Is Known? 
 Pulmonary arterial hypertension is commonly associated with iron deficiency.  
 Iron deficiency, even in the absence of anaemia, is associated with a poor clinical outcome in 
pulmonary arterial hypertension.  
What New Information Does This Article Contribute? 
 Chronic dietary iron deficiency induces structural changes in the pulmonary vasculature of 
the rat, associated with raised pulmonary arterial pressure and right heart hypertrophy. 
 The vascular changes are associated with altered mitochondrial function and bioenergetics. 
 Iron deficiency may have a direct effect on pulmonary vascular homeostasis and contribute 
adversely to the vascular pathology of pulmonary arterial hypertension.   
 
To address whether iron deficiency is simply a biomarker of morbidity or actively contributes to the 
vascular pathology of pulmonary arterial hypertension, we studied rats on a chronic iron deficient 
diet. Pulmonary hypertension was evident after 2 weeks and histological examination of the lungs 
showed striking remodelling of pulmonary arterioles, with medial hypertrophy, abnormal intimal 
endothelium and perivascular inflammatory cell infiltration. The pulmonary vasculature exhibited the 
biochemical signature of mitochondrial dysfunction, with a shift in cellular metabolism towards 
glycolysis. The pulmonary hypertension and vascular remodeling were attenuated in the presence of 
persistent chronic iron deficiency by treatments targeted at restoring normal mitochondrial activity 
(dichloroacetate) and inhibiting cellular proliferation (imatinib). Our observations suggest that iron 
availability has a direct impact on pulmonary vascular homeostasis and has implications for correcting 
iron deficiency in patients with pulmonary hypertension. 
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Supplemental Material 
Electrophysiology  
Mitochondrial inner membranes were isolated from control or IDD rat pulmonary arteries (n=3) and 
purified by centrifugation (Sacchetti et al., 2013). Patch clamp recordings were performed by forming 
a giga-ohm seal in intracellular solution (in mM: 120 KCl, 8 NaCl, 0.5 EGTA, 10 HEPES, pH 7.3) 
using an Axopatch 200B amplifier (Axon Instruments) at room temperature (22–25°C), Vm held at 
voltages between -100 mV to  +100 mV. Recording electrodes were pulled from borosilicate glass 
capillaries (WPI) with a final resistance in the range of 50-100MΩ. Signals were filtered at 5kHz 
using the amplifier circuitry. Data were analyzed using pClamp 10.4 software (Axon Instruments). 
Membrane currents under different experimental conditions were assessed by measuring peak 
membrane current minus the baseline current. In this experiment, the baseline membrane conductance 
was measured as the peak amount of current (pA) from the closed state. All current measurements 
were adjusted for the holding voltage, assuming a linear current-voltage relationship. The resulting 
conductances are expressed in pS according to the equation G = V/DI where G is conductance (pS), V 
is membrane holding voltage (mV) and DI is peak membrane current in pA - baseline current. Group 
data were quantified in terms of conductance. Data were expressed as mean ± SEM. 
 
 
Sacchetti, S., K.N. Alavian, E. Lazrove, and E.A. Jonas. F1FO ATPase Vesicle Preparation and 
Technique for Performing Patch Clamp Recordings of Submitochondrial Vesicle Membranes. JoVE. 
2013 (75) 
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Online Figure I. Effect of iron deficient diet (7mg iron/kg; TD.80396, Harlan, UK) on (a) 
unsaturated iron binding capacity (UIBC); (b) right ventricle (RV) systolic pressure; (c) right ventricle 
(RV) over body weight (bw) ratio; (d) left ventricle (LV+septum mass) over body weight (bw) ratio; 
(e) LV systolic pressure. Animals were fed for 2 (IDD 2WK), 3 (IDD 3WK) and 4 weeks (IDD 4WK) 
and compared to controls (CTR). (f) Effect of ferric carboxymaltose (75mg/Kg) on cardiac output; 
rats were fed with an iron deficient diet for 2 weeks, than ferric carboxymaltose was introduced along 
with the iron deficient diet for 2 additional weeks (IDD 4WK+Fe). Data are compared to 4 weeks iron 
deficient diet only (IDD 4WK) and controls (CTR). Group comparisons were made with one-way 
ANOVA and Bonferroni post hoc test. **P<0.01 and *p<0.05 vs control (CTR). 
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Online Figure II. a) Representative (200x) lung sections (EVG and SMA staining) demonstrating 
pulmonary vascular remodelling (red arrow) in 2, 3 and 4-week IDD rats (IDD 2WK, IDD 3WK, IDD 
4WK) b) Representative (200x) lung sections indicate macrophage (CD68
+
) infiltration in control 
(CTR), 4 week IDD rats (IDD 4WK) and 4 week IDD rats with ferric carboxymaltose treatment (IDD 
4WK+Fe). Sections were counterstained with Gill’s haematoxylin.  
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Online Figure III. a) Representative pictures indicate increased carbonic anhydrase (CAIX) 
expression in remodelled pulmonary vessels in IDD 4WK rat compared to control. Bar=50m. b) 
Representative western blot bands and summary data of lung Bcl2 protein expression (normalized to 
β-actin) in control and 4 weeks iron deficient (IDD 4WK) rats (n=5 each group). ** p<0.01 vs control. 
 
 
 
Online Figure IV. Effect of iron deficiency on mitochondrial inner membrane peak conductance 
levels. a) Representative patch clamp recording of control and iron deficient (IDD) rat pulmonary 
artery mitochondrial inner membrane vesicle at the indicated holding voltages (100 mV). Closed state 
of channel activity is indicated by the dotted red lines. b) Group data from patch clamp recordings of 
the peak conductance of control (n=5) and IDD (n=5), *p=0.0366. 
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